Literature DB >> 2730407

Photodynamic therapy for experimental intraocular melanoma using chloroaluminum sulfonated phthalocyanine.

J A Panagopoulos1, P P Svitra, C A Puliafito, E S Gragoudas.   

Abstract

Chloroaluminum sulfonated phthalocyanine (CASPc), a novel photosensitizing dye, was evaluated for treatment of experimental intraocular melanoma in 33 rabbit eyes. An argon ion pumped dye laser, operating at an emission of 675 nm, was used in a nonthermal mode to irradiate iris tumors in rabbits 24 hours after they received in intravenous dye injection (23 eyes). The effects of laser irradiation alone and dye alone were examined in ten control eyes. A threshold tumoricidal dose was established for photodynamic therapy with CASPc and laser irradiation. Vascular occlusion was produced in a well-circumscribed area corresponding to the boundaries of laser irradiation after CASPc injection. Tumors successfully treated with CASPc and laser irradiation were arrested in growth and exhibited no viable tumor cells on histologic examination. Control tumors continued rapid growth, unaffected by dye or laser. Our data indicate that CASPc demonstrates a strong photosensitizing effect on both tumor and normal tissue. These results suggest that CASPc is a potential photosensitizing compound that may be useful in the treatment of choroidal melanoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2730407     DOI: 10.1001/archopht.1989.01070010908039

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  6 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Feasibility of laser targeted photo-occlusion of ocular vessels.

Authors:  S Asrani; R Zeimer
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

3.  Occlusion of retinal vessels using targeted delivery of a platelet aggregating agent.

Authors:  Y Ogura; T Guran; K Takahashi; R Zeimer
Journal:  Br J Ophthalmol       Date:  1993-04       Impact factor: 4.638

4.  [Photodynamic therapy with verteporfin for uveal melanoma].

Authors:  J Wachtlin; N E Bechrakis; M H Foerster
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

5.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008

6.  Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy.

Authors:  Paul Lorenz Bigliardi; Bhimsen Rout; Aakanksha Pant; Viknish Krishnan-Kutty; Alex N Eberle; Ramasamy Srinivas; Brendan Adrian Burkett; Mei Bigliardi-Qi
Journal:  Sci Rep       Date:  2017-11-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.